Grace Gene Therapy

Company Overview

Snapshot

Founded in November 2024 by Fadi Assaf, Grace Gene Therapy operates with 1–10 employees. The company has secured funding across one round from one investor, NGT HealthCare II, to advance its gene therapy treatment for Parkinson's disease.

Business overview

Grace Gene Therapy is developing a revolutionary gene therapy treatment for Parkinson's disease, utilizing a first-in-class chemogenetic agent. Its core technology involves precise biological brain neuromodulators, specifically DREADDs (Designer Receptors Exclusively Activated by Designer Drugs), to target and adjust neural network problems in the basal ganglia. This biotech treatment aims to offer a unique solution to Parkinson's, distinguishing itself from mainstream dopaminergic system-based therapies. The company operates within the Health Tech & Life Sciences sector, focusing on Pharma & Medical Biotechnology and Drugs Discovery & Development, with a target market in Pharmaceuticals.

Company Intelligence Q&A

When was Grace Gene Therapy founded?

Grace Gene Therapy was founded in November 2024.

Who is the founder of Grace Gene Therapy?

Fadi Assaf is the Co-founder & CEO of Grace Gene Therapy.

What is Grace Gene Therapy's primary focus?

Grace Gene Therapy focuses on developing a gene therapy treatment solution for Parkinson's disease.

What technology does Grace Gene Therapy utilize for its treatment?

Grace Gene Therapy utilizes DREADDs (Designer Receptors Exclusively Activated by Designer Drugs) as a chemogenetic agent to precisely target and adjust neural networks in the brain for Parkinson's treatment.